Liquor Impacting Brain Activity (Credit-Freepik)
Many of us believe that we are great drinkers and that alcohol does not affect us as much. People who are able to drink without showing any sign of inebriation are known as social drinkers. In short, they are not addicted to alcohol but will not turn down the opportunity to have a good time! While it may seem like it doesn’t affect you, new studies suggest that it is just an illusion, even if you have high tolerance, alcohol affects your cognitive and motor functions more than you think.
The study reveals the below implications and techniques:
Think of it as the foundation for your brain's performance. When brain conductivity is high, information flows smoothly, and that helps your brain in rapid processing and response. On the other hand, low conductivity can hinder cognitive function, leading to slower thinking, impaired memory, and difficulties with coordination.
A study conducted at the Neuroscience Research Australia (NeuRA) and UNSW Science unveiled a startling connection between alcohol consumption and brain conductivity.
While many people brush off the effects of alcohol as temporary changes in behaviour, the reality is much more complex. Beyond the obvious impacts on coordination and judgment, alcohol significantly alters brain function. Alcohol dramatically slowed down brain activity, especially in areas responsible for decision-making, planning, and physical coordination. This decline was so significant that it resembled the brain changes seen in normal ageing. This means even one drink could temporarily accelerate the ageing process of your brain.
The implications of this research are far-reaching. It provides compelling evidence that alcohol consumption has a direct and measurable impact on brain function. The discovery that alcohol can significantly reduce brain conductivity opens new avenues for understanding the neurocognitive effects of alcohol abuse and dependence. While you may not feel like alcohol is affecting you and you have a high tolerance, it most definitely changes and affects your decision-making abilities and impulse control.
Furthermore, the MRI technique employed in the study could be a valuable tool for assessing the impact of other substances on the brain and for developing interventions to mitigate alcohol-related brain damage.
Credit: Hyperfine Inc
In a significant public health move, the All India Institute of Medical Sciences, New Delhi, has deployed India’s first portable MRI for bedside brain scans, marking an important milestone for neurological care across the country.
The MRI system, installed at the AIIMS’ Center for Neurological Conditions, will enable rapid brain imaging for critically ill patients in ICUs, emergencies, and neurosurgical care.
The ultra-low-field device can be wheeled directly to patients, eliminating the need for dedicated MRI suites or risky patient transfers.
“Bedside brain imaging transforms how we care for our most critically ill patients. At AIIMS, we manage thousands of stroke and ICU patients annually, where rapid neuroimaging is essential—yet transport to conventional MRI is often unsafe or impossible,” said Dr. Shailesh Gaikwad, Head, Department of Neuroimaging and Interventional Neuroradiology and Chief of Neuroscience Centre, AIIMS New Delhi, in a statement.
The Swoop MRI system, developed by US-based medical technology company Hyperfine, is the world's first FDA-cleared, portable, and ultra-low-field magnetic resonance brain imaging system capable of providing imaging at multiple points of care.
It is expected to improve rapid diagnosis in stroke, trauma, ICU monitoring, pediatrics, and post-operative neurosurgical care.
Across the world, portable bedside MRI systems are being used in hospitals in the US, Canada, Australia, the UK, New Zealand, and various EU countries.
“The Swoop system eliminates that barrier. Now our clinicians can obtain diagnostic images at the point of care, enabling faster decision-making in neurology, trauma, and critical care," Dr Gaikwad explained.
Also read: India’s Vaccine Initiatives: HPV For Girls, Indigenous Dengue Shot On The Horizon
He added that as AIIMS Delhi "serves as a referral center across India, this deployment signals what's possible when technology and clinical need align to advance neurological care”.
The technology enables faster decision-making in emergencies, in cases where conventional imaging is difficult or unsafe.
The installation in AIIMS Delhi follows regulatory approval in India, Hyperfine said in a statement.
Experts stated that the development could significantly expand access to brain imaging and strengthen research in point-of-care neurodiagnostics nationwide.

Conventional high-field MRI systems require dedicated shielded rooms, specialized infrastructure, and patient transport.
For critically ill patients in ICUs, trauma bays, neurosurgery wards, neonatal units, and emergency departments, transport is often not feasible. These limitations can delay diagnosis and treatment and impact outcomes.
On the other hand, the Swoop system
“Bringing the Swoop system to AIIMS New Delhi is an important milestone following regulatory approval last December. India has a significant unmet need for accessible brain imaging. Deployment at the country’s leading institution signals the start of bringing point-of-care brain MRI to sites of care and institutions across India, where it can serve clinicians and their patients across neurological conditions,” said Maria Sainz, President and CEO of Hyperfine.
The Swoop system deployment at AIIMS New Delhi also establishes a foundation for clinical research. The AIIMS New Delhi team plans to document outcomes, contribute to peer-reviewed publications, and advance India’s role in the growing global evidence base for point-of-care brain imaging.
Credit: AI generated image
Leprosy will soon be a notifiable disease in India’s national capital, Delhi, in a move to boost surveillance, improve early diagnosis and treatment, the state health department has said.
The Delhi Health Department has submitted the proposal, under the Delhi Epidemic Diseases Act, for necessary approval. Once approved, Delhi will join states like Tamil Nadu, Maharashtra, Karnataka, and West Bengal that have already made leprosy notifiable.
“Leprosy is completely curable. Making it a notifiable disease will help us find hidden cases, stop transmission, and ensure every patient gets standard treatment with dignity. This is a critical step towards honoring our commitment to a leprosy-free Delhi and supporting India’s journey towards the interruption of its transmission by 2030,” Health Minister Pankaj Singh said, in a statement.
More than 40 per cent of leprosy patients are managed by private health facilities in India, revealed a recent pan-India study. As a result, most go unreported to the National Leprosy Eradication Programme (NLEP).
Cases that go unreported continue to spike the risk of transmission. The variance in treatment protocols also raises the threat of drug resistance. WHO's Independent Evaluation of the NLEP program in India suggests that leprosy should be included in the list of diseases mandatory for notification.
According to the Ministry, the notification will mandate all government and private healthcare providers, including clinics, hospitals, and individual practitioners, to report every new leprosy case to the District Leprosy Officer.
Mandatory notification will
The proposed notification will be issued following the advice of the Delhi Government as per the GNCTD Act 1991. Detailed reporting formats and guidelines will be shared with all health institutions and practitioners across the National Capital Territory of Delhi.
Leprosy is also known as Hansen's disease. It is a chronic infectious disease that is caused by the bacterium Mycobacterium leprae. It affects the skin, peripheral nerves, upper respiratory tract mucosa, and eyes.
If it is not treated promptly, it could lead to permanent nerve damage, disabilities, and social stigma. However, the condition is fully curable with multidrug therapy, and early detection could prevent further complications.
Leprosy is also a neglected tropical disease (NTD), which occurs in more than 120 countries, with around 2,00,000 new cases reported every year.
India achieved the official elimination of leprosy as a public health problem (less than 1 case per 10,000 population) nationally in December 2005. However, the country still accounts for approximately 59 per cent of global annual new leprosy cases.
As per data from the Health Ministry, till March 2025, 31 states/UTs and 638 districts have achieved less than 1 case per 10,000 population of leprosy, with a prevalence rate of 0.57 per 10,000.
The NLEP now targets "Zero Transmission, Zero Leprosy" by 2027 through early detection, free multidrug therapy (MDT), and stigma reduction.
Under the NLEP, the government provides services such as free diagnosis and treatment (MDT) at all government health facilities, microcellular rubber footwears for patients, free assistive devices for leprosy patients, self-care kits for patients with ulcers, and reconstructive surgery for Grade 2 deformities with a welfare allowance of Rs 12,000.
All services under NLEP are available free of cost at all government health facilities.
Credit: AI generated image
The Supreme Court of India has urged the All India Institute of Medical Sciences (AIIMS) to set up an expert panel
to examine how brain death is certified in India.
The apex Court has sought to know whether additional tests, such as electroencephalogram (EEG) and angiogram, are needed to declare a person brain dead.
A bench of Justices Vikram Nath and Sandeep Mehta was hearing a petition filed by Kerala-based medic and activist S Ganapathy, alleging malpractices in brain death certification, Times of India reported.
Ganapathy alleged that patients who may not be brain dead are sometimes declared so to facilitate organ donation. The petition also questioned the reliability of the apnea test—the standard method used to confirm brain death—calling it subjective and claiming that the legal requirement of video graphing the procedure is often not followed.
Brain death, technically referred to as brain-stem death, is the irreversible end of all brain activity.
In India, according to the Transplantation of Human Organs (THO) Act, 1994 (Subsection 6 of Section 3), 'brain stem death' refers to the stage at which all functions of the brain stem have permanently and irreversibly ceased.
This is to be certified by a 'Board of Medical Experts' consisting of:
(1) The medical superintendent (MS)/In-Charge of the hospital in which 'brain stem' death has occurred,
(2) a specialist,
(3) a neurologist or a neurosurgeon nominated by the MS, from a panel approved by the Appropriate Authority, and the doctor under whose care the 'brain- stem' death has occurred.
Amendments in the THO Act 2011 have allowed the selection of a surgeon/physician and an anesthetist, if an approved neurosurgeon or neurologist is unavailable.
“Brain stem death has to be certified by a panel of four independent doctors, including a neurologist or neurosurgeon, and confirmed twice with a minimum gap of six hours. The process is carried out with due diligence and seriousness,” Dr Manjari Tripathi, head of neurology at AIIMS, was quoted as saying.
“While the guidelines require the team of doctors to meet and declare brain death at least twice, we end up doing it sometimes three times for the patients. The current guidelines require various bedside tests for the declaration of brain death. It does not specify the need for tests such as an EEG or angiogram,” added Dr. Tripathi.
Experts said additional tests could add to the system burden. EEG is not routinely recommended for brainstem death certification, while an angiogram is used only in select cases where the apnea test cannot be performed. Globally, the apnea test remains the gold standard. These criteria are clearly laid down and cannot be altered, said experts.
The Indian Express reported that the lack of knowledge even among physicians is a significant challenge in India.
This leads to several patients never being officially declared and asked to be organ donors.
An AIIMS-led study, published in the journal Neurology India last year, found that more than half the doctors — including neurosurgeons, neurologists, and critical care specialists who are most commonly included in the certification process — did not receive any training on brain death certification at the time of their graduation.
© 2024 Bennett, Coleman & Company Limited